Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Basilea Pharmaceutica AG
  6. News
  7. Summary
    BSLN   CH0011432447

BASILEA PHARMACEUTICA AG

(BSLN)
  Report
Delayed Swiss Exchange  -  11:31:24 2023-01-27 am EST
50.80 CHF   -1.74%
01/24Basilea Pharmaceutica : Updated January 24, 2023
PU
01/24Basilea Forecasts Return to Profit in FY22 Over Anti-infectives Focus
MT
01/24Basilea reports preliminary operating profit for 2022, significantly above guidance
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Basilea Pharmaceutica : Updated November 24, 2022

11/24/2022 | 11:54am EST

Focused on

Growth and Innovation

"Patients are at the heart of what we do"

Investor presentation

November 24, 2022

Table of contents

  • Executive summary
  • Portfolio
    • Antifungal
      • Cresemba® (isavuconazole)
    • Antibiotic
      • Zevtera® (ceftobiprole)
  • Financials & Outlook
  • Appendix

Focused on Growth and Innovation

Confidential/proprietary information of Basilea Pharmaceutica International Ltd, Allschwil - not for distribution

2

Executive summary

Experienced leadership team

Focused on Growth and Innovation

Confidential/proprietary information of Basilea Pharmaceutica International Ltd, Allschwil - not for distribution

4

At a glance

  • Focus on the treatment of serious bacterial and fungal infections
  • Recognized ability to establish and manage partnerships in both the development and commercial phase
  • Cresemba® and Zevtera® - two revenue generating hospital anti-infective brands
  • Commercial products complemented by programs which are in an earlier stage of development
  • On track to achieve sustainable profitability in 2023
  • Listed on SIX Swiss Stock Exchange, SIX: BSLN
  • Located in the Basel area life sciences hub, Switzerland

Focused on Growth and Innovation

Confidential/proprietary information of Basilea Pharmaceutica International Ltd, Allschwil - not for distribution

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Basilea Pharmaceutica AG published this content on 24 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 November 2022 16:53:06 UTC.


ę Publicnow 2022
All news about BASILEA PHARMACEUTICA AG
01/24Basilea Pharmaceutica : Updated January 24, 2023
PU
01/24Basilea Forecasts Return to Profit in FY22 Over Anti-infectives Focus
MT
01/24Basilea reports preliminary operating profit for 2022, significantly above guidance
GL
01/24Basilea reports preliminary operating profit for 2022, significantly above guidance
DJ
01/24Basilea Pharmaceutica Ltd Revises Earnings Guidance for the Year 2022
CI
01/11Basilea Pharmaceutica : Updated January 11, 2023
PU
01/11Basilea Lifts FY22 Revenue Outlook on Higher Contribution From Two Drugs
MT
01/11Basilea reports preliminary 2022 revenues, exceeding guidance, and provides portfolio u..
GL
01/11Basilea reports preliminary 2022 revenues, exceeding guidance, and provides portfolio u..
DJ
01/09Basilea Pharmaceutica Gets CHF20 Million Milestone Payment From Anti-fungal Drug Sales ..
MT
More news
Analyst Recommendations on BASILEA PHARMACEUTICA AG
More recommendations
Financials
Sales 2022 120 M 130 M 130 M
Net income 2022 -15,1 M -16,4 M -16,4 M
Net Debt 2022 89,7 M 97,4 M 97,4 M
P/E ratio 2022 -36,5x
Yield 2022 -
Capitalization 606 M 658 M 658 M
EV / Sales 2022 5,81x
EV / Sales 2023 4,97x
Nbr of Employees 177
Free-Float 88,1%
Chart BASILEA PHARMACEUTICA AG
Duration : Period :
Basilea Pharmaceutica AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BASILEA PHARMACEUTICA AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 50,80 CHF
Average target price 73,82 CHF
Spread / Average Target 45,3%
EPS Revisions
Managers and Directors
David Veitch Chief Executive Officer
Adesh Kaul Head-Corporate Development
Domenico Scala Chairman
Laurenz Kellenberger Chief Scientific Officer
Marc Engelhardt Head-Clinical Research
Sector and Competitors
1st jan.Capi. (M$)
BASILEA PHARMACEUTICA AG10.92%658
MODERNA, INC.7.58%72 745
LONZA GROUP AG17.24%42 787
IQVIA HOLDINGS INC.12.00%42 622
ALNYLAM PHARMACEUTICALS, INC.-2.55%28 465
SEAGEN INC.9.46%26 117